Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis [version 1; peer review: 1 approved, 2 approved with reservations]
Background: Several studies have revealed the potential use of tocilizumab in treating COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab may provide clinical benefits for cytokine release syndrome in COVID-19 patients. Methods: We searched for relevant studies in Pu...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2021-02-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/10-73/v1 |